QUESTIONS · ANSWERED FROM THE LITERATURE
Ipamorelin: the common questions, answered from the evidence.
Hunger, gut motility, IGF-1, the CJC-1295 stack, safety, and regulatory status — each answer pinned to what the studies actually show.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved, marketed drug, so there is no product to discontinue — the more accurate frame is that its clinical development stopped. Its only published Phase 2 trial, for postoperative ileus, missed its primary endpoint (time to first tolerated meal 25.3 h vs 32.6 h placebo, p=0.15) and no further trials followed [3]. In 2024 the FDA also tightened compounding-pharmacy access to it.
Will I gain weight on ipamorelin?
There is no controlled human trial measuring weight change on ipamorelin, so this cannot be answered from clinical data. Mechanistically, the ghrelin receptor it activates governs appetite, and ipamorelin stimulated adiposity and raised leptin in mice independent of GH [14]. Community reports describe both increased appetite and, separately, a gradual leaner look confounded by diet — all anecdotal, not findings [14].
Does ipamorelin help with gut motility?
On mechanism, plausibly: ghrelin-receptor agonists stimulate gastric motility, tone, and emptying, and the class was tested for gastroparesis and ileus [10]. But ipamorelin's own human GI trial — for postoperative ileus — missed its primary endpoint [3]. So the receptor rationale is real while ipamorelin's specific clinical motility benefit was not demonstrated [3][10].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the ghrelin receptor, GHS-R1a [1]. It releases growth hormone potently but without meaningfully raising cortisol or prolactin — the selectivity that earned it the title "the first selective growth hormone secretagogue" [1]. It is a research peptide, not an approved drug [3].
What does ipamorelin do for you?
In the research, ipamorelin triggers a single pulse of growth hormone by activating the ghrelin receptor [1][2]. In animals it raised longitudinal bone growth [4] and reduced chemotherapy-related weight loss [5]. In the one human efficacy trial, for postoperative ileus, it did not beat placebo [3]. Community-reported effects like deeper sleep are anecdotal, not clinical findings.
What is ipamorelin peptide?
Ipamorelin peptide is a five-amino-acid synthetic chain that mimics ghrelin at the GHS-R1a receptor to release growth hormone [1]. Built by Novo Nordisk in the 1990s (code NNC 26-0161), its defining feature is selectivity — a GH pulse without the cortisol and prolactin rise seen with earlier peptides like GHRP-6 [1]. Molecular formula C38H49N9O5 [1].
What are the risks of ipamorelin?
The honest risk picture is dominated by missing data: no Phase 3 trial and no long-term human safety database [3]. Documented concerns include a class-level cardiotoxicity signal in rats from a related ghrelin agonist [6], theoretical GH/IGF-1 cancer concerns [1], and unverified purity of gray-market material. The seven-day Phase 2 trial showed no ipamorelin-specific safety signal in that short window [3].
Does ipamorelin reduce belly fat?
No human trial has tested ipamorelin for fat loss. The most relevant in-vivo data is a 2024 ferret study where intraperitoneal ipamorelin inhibited cisplatin-induced weight loss by about 24% — an anti-wasting effect, not fat reduction [5]. Some community users report a gradually leaner look over weeks, but that is anecdotal and confounded by diet and training, not a clinical finding [5].
What are the downsides of ipamorelin?
The central downside is evidence: ipamorelin's only published efficacy trial failed, and it has no approved use anywhere [3]. Practical downsides reported in communities include facial flushing, increased hunger, mild water retention, injection-site irritation, and a fading response over months — all anecdotal [3]. Long-term human safety is simply uncharacterized [3].
What does CJC-1295 and ipamorelin do?
CJC-1295 and ipamorelin act on two different receptors to release growth hormone: ipamorelin on the ghrelin receptor (GHS-R1a), CJC-1295 on the GHRH receptor [1]. They are paired because those pathways are complementary [1]. The combination has never been tested as a combination in any controlled trial, so its support is the separate single-agent pharmacology, not combined outcome data [3].
Does ipamorelin increase IGF-1?
Not consistently. Growth hormone can raise hepatic IGF-1, but in short rat studies ipamorelin increased bone growth with no measurable change in total IGF-1 or IGF-binding proteins [4]. So IGF-1 elevation is context-dependent and was not a reliable feature of the short-term rodent data [4]. No human IGF-1 dataset at research-use doses exists.
How does CJC-1295 ipamorelin work?
The pairing works by hitting two complementary GH-release pathways at once. Ipamorelin activates the ghrelin receptor (GHS-R1a), driving a calcium-dependent GH pulse [1]; CJC-1295, a GHRH analog, activates the separate GHRH receptor via a cAMP pathway [1]. Combining them is the standard rationale for stacking, though no trial has tested the combination for any outcome [3].
How much CJC-1295 ipamorelin should I take?
This review does not provide a dose. There is no approved or established human dose for ipamorelin, alone or with CJC-1295, and no controlled trial has tested the combination [3]. Ipamorelin's human studies used intravenous dosing in controlled settings [2][3]; the subcutaneous stacks shared online have no peer-reviewed dosing basis.
Does CJC-1295 ipamorelin work?
No controlled human trial has tested the CJC-1295 + ipamorelin combination for any endpoint. Each peptide reliably produces a GH pulse on its own in animal and human pharmacology [1][2], which is the basis for the pairing, but the combination's popularity rests on that mechanism plus anecdote, not outcome data [3].
How to reconstitute CJC-1295 ipamorelin 5mg?
These peptides ship as a lyophilized (freeze-dried) powder that is dissolved before research handling. General peptide-handling literature describes reconstitution with bacteriostatic water and refrigeration of the solution, since peptides degrade with heat and freeze-thaw [2]. This is a general handling note, not a clinical preparation or dosing instruction — ipamorelin has no approved human preparation [3].
How long does ipamorelin stay in your system?
Ipamorelin's terminal half-life in healthy human volunteers is approximately two hours (intravenous), with clearance 0.078 L/h/kg [2]. The growth-hormone response is a single discrete pulse peaking around 40 minutes after dosing [2]. By the usual five-half-life rule of thumb, the peptide itself is largely cleared within roughly ten hours, though detection methods for anti-doping purposes differ [2].
Does ipamorelin make you hungry?
Possibly, on mechanism: ipamorelin activates the ghrelin (hunger) receptor, and ghrelin-receptor agonists induce feeding in animals [15]. Some community members report increased hunger after injecting, described as milder than with GHRP-6 — anecdotal, not clinical [15]. No controlled human trial has measured ipamorelin's effect on appetite. The full appetite picture is on does ipamorelin make you hungry.
Does ipamorelin increase appetite?
In animal pharmacology, the ghrelin-receptor class it belongs to increases feeding, and ipamorelin stimulated adiposity in mice independent of GH [14][15]. In people, there is no controlled appetite trial. Community reports of an appetite uptick after injection are common but anecdotal and not a clinical finding [14][15].
What does ipamorelin peptide do?
Ipamorelin peptide activates the ghrelin receptor to release a clean pulse of growth hormone — potent GH release without raising cortisol or prolactin [1]. In humans that pulse peaks about 40 minutes after dosing [2]. Beyond GH, its receptor sits in the gut and appetite centers, so its biology touches motility and hunger [10][15]. A fuller account is on what does ipamorelin peptide do.
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes (0.67 h) after an intravenous dose in humans [2]. Any subjective effects people describe — such as sleep changes — are reported anecdotally over days to weeks, not measured in trials [2]. The acute GH response itself is essentially immediate within that ~40-minute window [2].
Does ipamorelin cause water retention?
Growth-hormone elevation is associated with sodium and water retention, so mild fluid retention is mechanistically plausible, and some community users report transient puffiness in the early weeks — anecdotal, not a clinical finding [3]. The seven-day Phase 2 trial recorded comparable adverse-event rates between ipamorelin and placebo without a distinct water-retention signal [3].
Where to inject CJC-1295 ipamorelin?
This review does not provide administration instructions. In the published human research, ipamorelin was given intravenously in controlled clinical settings [2][3]. The subcutaneous self-injection common in community use has no published human safety or pharmacokinetic characterization, and no approved human route exists for ipamorelin [3].